Actively Recruiting
Herombopag Treated T-DM1 Induced Platelet Reduction
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-12-02
56
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.
CONDITIONS
Official Title
Herombopag Treated T-DM1 Induced Platelet Reduction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years, any gender
- Diagnosed with breast cancer confirmed by histological or cytological examination
- Previously treated with neoadjuvant anti-HER-2 therapy then T-DM1 adjuvant therapy
- Experienced grade 2 or higher thrombocytopenia during prior T-DM1 treatment, now with platelet count restored to 100 x 10�9/L and 200 x 10�9/L before next treatment
- ECOG performance status of 0 to 2
- Planned to receive at least two more T-DM1 treatment cycles at consistent doses
- Expected survival of at least 12 weeks and able to tolerate treatment for two or more cycles
- Able to comply with treatment and follow-up requirements
You will not qualify if you...
- History of other malignant tumors diagnosed within the past 3 years
- Mental or neurological disorders preventing cooperation
- Scheduled for or previously had organ or bone marrow transplantation
- Hematopoietic system disorders other than chemotherapy-induced thrombocytopenia, including leukemia, immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, or myelodysplastic syndrome
- History of arterial or venous thrombotic events within 6 months before screening
- Severe bleeding events within 2 weeks before screening, such as gastrointestinal or central nervous system bleeding
- Participation in a similar drug clinical trial within 4 weeks before enrollment
- Pregnant or breastfeeding women
- Known allergy to the study drug
- Deemed ineligible by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
T
Tao Qin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here